胆甾醇聚醚-10 | 27321-96-6

• 分子结构分类: 有机化合物 - 脂质和类脂质分子 - 类固醇和类固醇衍生物
• 中文名称: 胆甾醇聚醚-10
• 中文别名: 胆甾醇聚醚-20；胆甾醇聚乙二醇；胆甾醇聚醚-24
• 英文名称: 2-[[10,13-dimethyl-17-(6-methylheptan-2-yl)-2,3,4,7,8,9,11,12,14,15,16,17-dodecahydro-1H-cyclopenta[a]phenanthren-3-yl]oxy]ethanol
• CAS: 27321-96-6
• 化学式: C₂₉H₅₀O₂
• 分子量: 430.715
• InChiKey: NPYXBHZQVNRAOF-UHFFFAOYSA-N

物化性质

• LogP：
  9.798 (est)

计算性质

• 辛醇/水分配系数(LogP)：
  8.4
• 重原子数：
  31
• 可旋转键数：
  8
• 环数：
  4.0
• sp3杂化的碳原子比例：
  0.93
• 拓扑面积：
  29.5
• 氢给体数：
  1
• 氢受体数：
  2

安全信息

• WGK Germany：
  2

文献信息

• POLYMER-CARBOHYDRATE CONJUGATES FOR DRUG DELIVERY TECHNOLOGY
  申请人：Wu Nian

  公开号：US20150157721A1

  公开（公告）日：2015-06-11

  The invention comprises compounds, methods of making, and methods of using. The compounds may have a linear or cylic backbone and three or four appended functional groups: one or two lipohilic compounds including sterols or “fat soluble” vitamins, one or two hydrophilic polymer, and one or two carbohydrate. A group of polymer-carbohydrate conjugates having a central backbone and three appended functional groups are disclosed wherein one lipophilic compound is void of both steroid acids. The conjugate may have fatty acids as the primary lipophilic carrier, one hydrophilic polymer, and one carbohydrate. Specific functional groups may be selected for specific applications in formulating pharmaceuticals, cosmetics, nutriceuticals, and the like. Typical coupling reaction of the conjugates may involve one or more or combinations or in series of alkylation including N-alkylation or O-alkylation, etherification, esterification and amidation chemical processes. A variety of linkers between the backbone and functional groups may also be selected to modify the carriers or center backbones for the coupling reactions and optimize performance of the conjugates.

  该发明包括化合物、制备方法和使用方法。这些化合物可能具有线性或环状的骨架，以及三个或四个附加的功能基团：一个或两个疏水化合物，包括固醇或“脂溶性”维生素，一个或两个亲水性聚合物，以及一个或两个碳水化合物。公开了一组具有中心骨架和三个附加功能基团的聚合物-碳水化合物共轭物，其中一个疏水性化合物不含类固醇酸。该共轭物可能以脂肪酸作为主要疏水载体，一个亲水性聚合物和一个碳水化合物。特定的功能基团可以根据在制备药物、化妆品、营养保健品等方面的具体应用而选择。共轭物的典型偶联反应可能涉及一种或多种或组合或串联的烷基化，包括N-烷基化或O-烷基化，醚化，酯化和酰胺化化学过程。还可以选择各种连接剂连接骨架和功能基团之间，以修改载体或中心骨架以进行偶联反应并优化共轭物的性能。
• Compositions and methods for the treatment of presbyopia
  申请人：Presbyopia Therapies, LLC

  公开号：US10052313B2

  公开（公告）日：2018-08-21

  The invention provides compositions and methods for the treatment of presbyopia. The compositions preferably comprise aceclidine and a polyol. The compositions optionally contain a cycloplegic agent, a surfactant, a viscosity enhancer, an osmolarity modifier and a preservative.

  本发明提供了治疗老花眼的组合物和方法。这些组合物最好包含阿西环定和多元醇。组合物中还可选择含有一种抗老花剂、一种表面活性剂、一种增粘剂、一种渗透压调节剂和一种防腐剂。
• Contact lens compositions and methods for the treatment of presbyopia
  申请人：Presbyopia Therapies, LLC

  公开号：US10307408B2

  公开（公告）日：2019-06-04

  The invention provides contact lens and contact lens storage compositions and methods for the treatment of presbyopia. The contact lens and contact lens storage compositions preferably comprise aceclidine and a cryoprotectant. The compositions optionally contain a cycloplegic agent.

  本发明提供了用于治疗老花眼的隐形眼镜和隐形眼镜储存组合物及方法。隐形眼镜和隐形眼镜储存组合物最好包含阿西环定和低温保护剂。这些组合物还可选择含有一种抗老花剂。
• Methods for the treatment of myopia
  申请人：Lenz Therapeutics, Inc.

  公开号：US11344538B2

  公开（公告）日：2022-05-31

  The invention provides methods for the treatment of myopia. The compositions preferably comprise aceclidine. The compositions optionally contain a surfactant, a viscosity agent, a polyol and/or a selective α-2 adrenergic receptor agonist.

  本发明提供了治疗近视的方法。组合物中最好含有阿西环定。组合物还可选择含有表面活性剂、增粘剂、多元醇和/或选择性α-2肾上腺素能受体激动剂。
• COMPOSITIONS AND METHODS FOR THE TREATMENT OF PRESBYOPIA
  申请人：Presbyopia Therapies, LLC

  公开号：EP3429584A1

  公开（公告）日：2019-01-23